Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
Platina 250, 300 & 350 Lamitubes have been recognized by the Association of Plastic Recyclers (APR), USA as meeting or exceeding the strict APR HDPE critical guidance criteria on recyclability
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
Two out of three people under the age of 40 are at risk of prediabetes
The aim is to support Pharmacovigilance programme across the countries in the region
This test is inexpensive and results are available immediately as compared to the genetic test
Subscribe To Our Newsletter & Stay Updated
